2020-05-29| Technology

What to Expect from the ASCO20 Virtual Program

by GeneOnline
Share To

Photo Courtesy: ASCO

Taking the COVID-19 pandemic into consideration, last March, the organizers of the American Society of Clinical Oncology (ASCO), decided to convert their highly regarded annual meeting into a virtual format. Originally scheduled to take place in Chicago for 5 days, the conference will now transpire as an online program between May 29 – 31. Here is a brief preview of what to expect from the event.

The ASCO annual meeting is more than just a scientific congregation of physicians, researchers, and industry professionals reporting on the latest advances in cancer research. It is also an opportunity for education and patient advocacy. While a virtual program may not be an ideal replacement for the in-person meeting to achieve its full potential, the decision is the right one, considering the circumstances. Besides, it offers access to a horde of participants around the globe, who might have otherwise skipped the event. We attempted to give a glimpse of what to look forward to at the conference.

Anticipated Clinical Trial Results

In their official website, ASCO announced some of the top studies to be presented at the meeting. They include:

Plenary Session
Other Sessions
Select Company Presentations
  1. The use of tumor mutational burden (TMB) as a pan-tumor genomic biomarker across a variety of cancers
  2. FMI and Flatiron Health’s clinico-genomic database demonstrating that the combination of TMB and PD-L1 can better predict immunotherapy response in lung cancer patients (TPS2087)




© All rights reserved. Collaborate with us:
Related Post
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
Pharmacogenomics (PGx): Tailoring Medicine to Your Genes
Roche Delivering on Malaria Screening Solutions for Blood Donation
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top